Status:
COMPLETED
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Lead Sponsor:
University of Chicago
Conditions:
Acute Myelogenous Leukemia
Lymphoid Leukemia
Eligibility:
All Genders
Up to 100 years
Phase:
PHASE2
Brief Summary
Objectives: 1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. 2...
Eligibility Criteria
Inclusion
- Zubrod performance status 2 (See Appendix B).
- Life expectancy is not severely limited by concomitant illness.
- Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol.
- Serum creatinine \<1.5 mg/dL or Creatinine Clearance \>50 ml/min .
- Serum bilirubin 2.0 mg/dl, SGPT \<3 x upper limit of normal
- No evidence of chronic active hepatitis or cirrhosis.
- HIV-negative
- Patient is not pregnant
- Patient or guardian able to sign informed consent.
Exclusion
- N/A
Key Trial Info
Start Date :
November 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00683046
Start Date
November 1 2001
End Date
December 1 2014
Last Update
November 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637